Our Management Team
Leon Rudakov, PhD, President and Chief Technology Officer
He designed, built and lead the commercialization of ArtVentive EOSTM device. Dr. Rudakov holds 34 patents related to the EOS family of devices.
Prior to starting ArtVentive Medical Group Dr. Rudakov spent more than 25 years in corporate management, R&D and engineering.
He has held several executive management and leading R&D positions with international corporations including Booz Allen & Hamilton, and various medical device startup companies.
Dr. Rudakov pioneered the development and commercialization of various cardiovascular devices, including a stent graft for coronary artery bypass surgery and a unique neurovascular device for the treatment of intracranial aneurysms.
He has developed the Coronary Stent that has been sold to Goodman Corporation of Japan and approved as a Goodman stent in Japan. His later works on a next coronary stent designs were followed by obtaining the CE Mark for commercial use of the device in South East Asia.
Dr. Rudakov holds PhD from Moscow Aviation Institute in Mechanical Engineering, Design Management and Optimization and he is a graduate of Duke University, Fuqua School of Business, N.C. Business Executive Program.
Henk van der Laak, Director of Sales, EMEA
He brings extensive experience in the international medical devices industry, in particular in the interventional radiology, cardiology, and endovascular field.
Before joining ArtVentive, he held the position of regional Sales Director for Europe at HemoCue AB, a Danaher Company. Mr. van der Laak previously served in European sales leadership roles with SenoRx Inc. and Cordis Corporation, a Johnson & Johnson Company. He established direct sales, marketing and logistics operations, including the set-up of a European central warehouse, and managed international distributor networks in the EMEA region. Mr. van der Laak was involved in the market introduction of new interventional vascular technologies, thereby building successful relationships with KOL’ s across Europe.
Neil Reithinger, Chief Financial Officer
Neil Reithinger serves as CFO of ArtVentive Medical Group.
Mr Reithinger is the Founder and President of Eventus Advisory Group, LLC, a CFO-services firm that specializes in capital advisory and SEC compliance for publicly-traded and emerging growth companies. He is also the President of Eventus Consulting, P.C., a registered CPA firm in Arizona. Mr. Reithinger is an experienced CFO with over 22 years of diversified practice in a broad range of industries including life sciences, consumer products, mining, energy services and digital media. Mr. Reithinger has successfully created initiatives to streamline accounting processes and SEC compliance, develop capital markets strategies, restructure and optimize operations and spearhead due diligence for financings and acquisitions. He has strong leadership and administrative skills, experience in building efficient processes and managing and developing accounting and finance staff.
Since August 2014, Mr. Reithinger has served as the CFO of Orgenesis Inc., a publicly-traded cell therapy and regenerative medicine company with a technology focused on curing Type 1 diabetes. Prior to forming Eventus Advisory Group, LLC in December 2009, Mr. Reithinger served in various executive management positions including COO & CFO of New Leaf Brands, Inc., a branded beverage company, CEO of Nutritional Specialties, Inc., a nutritional supplement company (that was acquired by Nutraceutical International, Inc. NASDAQ: NUTR), Chairman, CEO & President of Baywood International, Inc., a publicly-traded nutraceutical company. Prior to that, Mr. Reithinger worked for Bank of America. Mr. Reithinger earned a B.S. in Accounting from the University of Arizona and is a Certified Public Accountant. He is a Member of the American Institute of Certified Public Accountants and the Arizona Society of Certified Public Accountants.
Tyson Brill, Director of Sales, USA
Mr. Brill benefits from more than twelve years of progressive responsibility in the medical device industry. Prior to joining ArtVentive, he managed and developed new business opportunities for Infraredx, Inc. (acquired by Nipro Corporation TYO:8086) where he commercially launched the first and only available catheter to combine near-infrared spectroscopy (NIRS) and intravascular ultrasound (IVUS) technologies to identify intracoronary lipid-core plaques long suspected of causing heart attacks.
Mr. Brill has extensive startup, sales planning and management experience from previous roles at AccessClosure (purchased by Cardinal Health, Inc. NYSE:CAH) and GE Healthcare (NYSE:GE). He holds a Bachelor of Science degree from the University of Illinois at Urbana-Champaign.
Mikhail holds a B.S. degree in Business Administration from Winona State University together with a J. D. and an LL.M. in Taxation from the University of Denver. Mikhail is admitted to practice law in New York, Washington D.C. and Colorado. He is also admitted to practice law in United States Tax Court.
Scientific Advisory Board
The Scientific Advisory Board (SAB) consists of well-recognized international members of the medical and scientific communities related to areas pertinent to AVMG’s development.
The mandate of the SAB is to assist the Company in its identification, development, and cutting-edge direction of opportunities and product development. The Board also advises on clinical studies and scientific and regulatory affairs.
Philippe Gailloud, MD - Chairman
He has been working in the field of image-guided therapy for more than 15 years.
Anthony Venbrux, MD
Dr. Venbrux received his Doctor of Medicine from the University of Washington’s School of Medicine and received his fellowship at the Walter Reed Army Medical Center, Washington, DC, in the department of Angiography and Interventional Radiology.
Dr. Venbrux has served as chairperson of the Cardiovascular Radiology Council of the American Heart Association since 2001.
Adriaan Moelker, MD, PhD
Jonathan S. Reiner, MD
Dr. Reiner’s papers have been published in over 85 journals and publications pertaining to Cardiovascular Disease and Interventional Cardiology. His work spans over 21 years and he has been honored with many awards, including the Squibb Society award for Cardiac Angiography and the Intervention Fellowship for Research in Cardiac Imaging. He is a Fellow within the American College of Cardiology and member of the American Heart Association.
Robert Gannan, MD, PhD
Dr. Gannan is an international speaker at medical conferences on scientific and business related topics, such as therapeutic endoscopic retrograde cholangiopancreatograpy, development of biliary stents and inflammatory bowel disease and development of ASCs (ambulatory surgery centers).
He has written and co-authored over 100 publications and presentations, in addition to being a member of a number of Scientific Advisory Boards to leading corporations within the global medical community. He is a member of the Strategic Planning Committee for the University of Rochester Medical School. He also teaches gastroenterology and advanced endoscopy in developing countries.
Andrew Akman, MD
Dr. Akman received his Doctor of Medicine and Masters in Business Administration May 2003 from Tufts University School of Medicine in Boston prior to his Fellowship in Vascular and Interventional Radiology at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Akman has written 13 publications, educational exhibits, and presentations, in addition to being a member of the Society of Interventional Radiology.